Exact sciences corporation stock.

09-Oct-2023 ... MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...

Exact sciences corporation stock. Things To Know About Exact sciences corporation stock.

MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, ...Nov 1, 2023 · Exact Sciences Corp (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced on November 1, 2023, that the company generated revenue of $628.3 million for the third ... The stock price for Madison-based cancer screening and diagnostic test company Exact Sciences Corp. soared Wednesday after the company reported higher-than-expected sales in the first quarter.MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Share Price. EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the ...

Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 7.65% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...

Indian Oil Corporation Ltd., Tata Motors Ltd., Reliance Industries Ltd. and the State Bank of India are four of the biggest joint stock companies of India. A joint stock company is simply a business entity in which stakes are owned jointly ...

Exact Sciences Corporation EXAS reported a net loss of 42 cents per share for first-quarter 2023, ... (EW) : Free Stock Analysis Report. Exact Sciences Corporation (EXAS) : Free Stock Analysis ...Exact Sciences Corporation‘s (EXAS Quick Quote EXAS - Free Report) shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the ...MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, ... These non-GAAP measures include adjustments like stock-based compensation, acquisition and …The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company.MADISON, Wis., Oct. 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer detection, genomic testing, and treatment guidance at the 2023 European Society for Medical Oncology (ESMO) Congress, October 20-24, in Madrid, Spain.

Exact Sciences Corp. will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium (SABCS). In cooperation with several leading breast cancer research organizations, Exact Sciences will present late-breaking data and a study included in …

Corporate Impact and Community Relations. Our Collaborations. Contact Us. Newsroom. News & Stories. ... Stock Information. ... CANCER IS DETECTED TOO LATE. Our mission at Exact Sciences is to eradicate cancer and the suffering it causes — through tests that help prevent it, detection that finds it earlier, and guidance for its successful ...

Oncotype DX ® Test Recognized as the 'Preferred' and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer. Update based on first results from the independent RxPONDER study presented at the 2020 San Antonio Breast Cancer Symposium 1. Madison, Wis., March 31, 2021 - Exact Sciences today …Exact Sciences Corporation is a leader in global cancer screening and diagnostics and is undertaking rapid global expansion through several new acquisitions. ... but confuses the stock analysts ...View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. About Exact Sciences Corp. ... Stock-based compensation including the incremental fair value of assumed stock awards and accelerated vesting from post-acquisition qualified termination events was $4.2 million and $8.2 million for the three and nine months ended September 30, 2020.Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.Exact Sciences Corp. historical stock charts and prices, analyst ratings, financials, and today's real-time EXAS stock price.Nov 22, 2023 · Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...

Exact Sciences Corporation (EXAS) Shares Pulled Back in Q3. Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2023 investor letter.Dec 1, 2023 · Sentiment. Exact Sciences (EXAS) has an AI Score of /10 (Buy) because its overall probability of beating the market (S&P 500) in the next 3 months (43.63%) is +42.63% vs. the average probability (%) of US stocks analyzed by our Artificial Intelligence. The AI-powered overall analysis of Exact Sciences (EXAS) is based on the fundamental ... Imperialism exists today, but not in the exact form practiced during the Roman Empire or the British Empire. Capitalism is a major driver of modern imperialism as corporations, such as banks and oil companies, expand globally to generate mo...30,994.67. -0.26%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.OQ) real-time stock quotes, news, price and financial information from Reuters to ...5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024. We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.Get EXACT Sciences Corporation (EXAS) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial ...© Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.111.2.6 5.111.2.6

Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...

The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ...Mar 3, 2023 · Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 8.31% so far this month. During the month of March, Exact Sciences Corp’s stock price has reached a high of $67.82 and a low of $60.85. Over the last year, Exact Sciences Corp has hit prices as high as $76.94 and as low as $29.27. Year to date, Exact ... Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...Stock Information; Financial Information. SEC Filings; Quarterly Results; Analyst Coverage; Interactive Analyst Center; Email Alerts; Contact UsExact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqSep 18, 2023 · In related news, CFO Jeffrey Thomas Elliott recently sold 30,210 shares of Exact Sciences’ stock on August 21st. The average selling price was $82.92 per share, resulting in a total transaction amounting to $2,505,013.20. This transaction was made public through a filing with the SEC, which can be accessed through the provided link. Get the latest information on Exact Sciences Corp (EXAS), a biotechnology company that develops and sells diagnostic tests for cancer screening and treatment. See its stock price, financial performance, earnings, balance sheet, cash flow, and more.Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA …

Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 8.31% so far this month. During the month of March, Exact Sciences Corp’s stock price has reached a high of $67.82 and a low of $60.85. Over the last year, Exact Sciences Corp has hit prices as high as $76.94 and as low as $29.27. Year to date, Exact ...

May 15, 2023 · On Nov 8, 2019, Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based ...

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...Jul 19, 2023 · Financial Performance. Exact Sciences reported Q1 2023 results with total revenue of $602.5M (up 24% from 2022). Core revenue increased by 33% to $597.8M, led by a 45% surge in screening revenue ... MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, ... Represents stock-based compensation expense and 401(k) match expense as the …Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023. Nov 02 + 1 more update. Forecast to breakeven in 2025 Oct 26. No longer forecast ... Lead Independent Director exercised options to buy US$363k worth of stock. Jan 19. Insider notifies of intention to sell stock Jan 13. An Intrinsic Calculation For Exact ...Exact Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Ultragenyx (RARE), a stock from the same industry, has gained 6.7%.Exact Sciences Corporation issued to certain of the selling stockholders of Paradigm an aggregate of 381,047 shares of common stock as initial merger consideration for their ownership in Paradigm. In addition, Exact Sciences Corporation withheld 45,338 shares of common stock payable as additional merger consideration to such selling ...The latest EXACT Sciences stock prices, stock quotes, news, and EXAS history to help you invest and trade smarter. ... EXACT Sciences Corp. is a cancer screening and diagnostics company.

Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.10-Apr-2023 ... MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic ...MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.Dec 1, 2023 · 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ... Instagram:https://instagram. will a government shutdown affect social security benefitshow much does a gold brick costbest health insurance for contractorshow to buy stock on otc market MADISON, Wis., Nov. 3, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $523 million for the third quarter ended September 30, ... Represents severance, accelerated stock-based compensation expense, ...In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ... julie zweigiphone 15 pro max shipments Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 1.28% so far this month. During the month of April, Exact Sciences Corp’s stock price has reached a high of $68.77 and a low of $63.37. Over the last year, Exact Sciences Corp has hit prices as high as $72.19 and as low as $29.27. Year to date, Exact ... how much is a dollar coin from 1979 worth Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited ...As of November 29, 2023, Exact Sciences Corp had a $11.7 billion market capitalization, compared to the Biotechnology & Medical Research median of $79.5 million. Exact Sciences Corp’s stock is NA in 2023, NA in the previous five trading days and up 56.77% in the past year. Currently, Exact Sciences Corp does not have a price …View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.